822 related articles for article (PubMed ID: 25445642)
1. Preventive azithromycin treatment reduces noninfectious lung injury and acute graft-versus-host disease in a murine model of allogeneic hematopoietic cell transplantation.
Radhakrishnan SV; Palaniyandi S; Mueller G; Miklos S; Hager M; Spacenko E; Karlsson FJ; Huber E; Kittan NA; Hildebrandt GC
Biol Blood Marrow Transplant; 2015 Jan; 21(1):30-8. PubMed ID: 25445642
[TBL] [Abstract][Full Text] [Related]
2. Idiopathic pneumonia syndrome in mice after allogeneic bone marrow transplantation.
Shankar G; Bryson JS; Jennings CD; Morris PE; Cohen DA
Am J Respir Cell Mol Biol; 1998 Feb; 18(2):235-42. PubMed ID: 9476911
[TBL] [Abstract][Full Text] [Related]
3. Cobalt protoporphyrine IX-mediated heme oxygenase-I induction alters the inflammatory cytokine response, but not antigen presentation after experimental allogeneic bone marrow transplantation.
Ewing P; Hildebrandt GC; Planke S; Andreesen R; Holler E; Gerbitz A
Int J Mol Med; 2007 Sep; 20(3):301-8. PubMed ID: 17671733
[TBL] [Abstract][Full Text] [Related]
4. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
Li JM; Waller EK
Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
[TBL] [Abstract][Full Text] [Related]
5. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
[TBL] [Abstract][Full Text] [Related]
6. Preimplantation factor reduces graft-versus-host disease by regulating immune response and lowering oxidative stress (murine model).
Azar Y; Shainer R; Almogi-Hazan O; Bringer R; Compton SR; Paidas MJ; Barnea ER; Or R
Biol Blood Marrow Transplant; 2013 Apr; 19(4):519-28. PubMed ID: 23266739
[TBL] [Abstract][Full Text] [Related]
7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
8. APCs in the liver and spleen recruit activated allogeneic CD8+ T cells to elicit hepatic graft-versus-host disease.
Zhang Y; Shlomchik WD; Joe G; Louboutin JP; Zhu J; Rivera A; Giannola D; Emerson SG
J Immunol; 2002 Dec; 169(12):7111-8. PubMed ID: 12471148
[TBL] [Abstract][Full Text] [Related]
9. [Influence of mouse genetic engineering regulatory T cells infusion on post-allogeneic bone marrow transplantation acute graft-versus-host disease in mice].
Cao J; Li L; Chen C; Zeng LY; Li ZY; Pan XY; Xu KL
Zhonghua Xue Ye Xue Za Zhi; 2011 Feb; 32(2):83-8. PubMed ID: 21429372
[TBL] [Abstract][Full Text] [Related]
10. Combination cell therapy using mesenchymal stem cells and regulatory T-cells provides a synergistic immunomodulatory effect associated with reciprocal regulation of TH1/TH2 and th17/treg cells in a murine acute graft-versus-host disease model.
Lim JY; Park MJ; Im KI; Kim N; Jeon EJ; Kim EJ; Cho ML; Cho SG
Cell Transplant; 2014 Apr; 23(6):703-14. PubMed ID: 23452894
[TBL] [Abstract][Full Text] [Related]
11. [Effects of immature dendritic cells genetically modified to express sTNFR I on graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) in allogeneic bone marrow transplantation mice].
Wang SH; Li DP; Zhang YJ; Zhang P; Zeng LY; Pan XY; Xu KL; Huang YH
Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):88-93. PubMed ID: 22730654
[TBL] [Abstract][Full Text] [Related]
12. Control of mouse graft-versus-host disease following allogeneic bone marrow transplantation by blocking the CD28/B7 signaling pathway with lentiviral vector-mediated RNA interference.
Sang W; Zhou C; Cheng N; Li Z; Zeng L; Xu K
Immunol Lett; 2011 May; 136(2):194-202. PubMed ID: 21277900
[TBL] [Abstract][Full Text] [Related]
13. [Role of TJU103 in prevention of graft-versus-host disease after allogeneic stem cell transplantation in mice].
Wang SB; Guo KY; Hu DM; Yin B
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jun; 26(6):810-3. PubMed ID: 16793606
[TBL] [Abstract][Full Text] [Related]
14. Lymphopenia-induced proliferation of donor T cells reduces their capacity for causing acute graft-versus-host disease.
Maeda Y; Tawara I; Teshima T; Liu C; Hashimoto D; Matsuoka K; Tanimoto M; Reddy P
Exp Hematol; 2007 Feb; 35(2):274-86. PubMed ID: 17258076
[TBL] [Abstract][Full Text] [Related]
15. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.
Fowler DH; Breglio J; Nagel G; Eckhaus MA; Gress RE
J Immunol; 1996 Dec; 157(11):4811-21. PubMed ID: 8943383
[TBL] [Abstract][Full Text] [Related]
16. [The role of third-party tolerogenic dendritic cells in the prevention of acute graft-versus-host-disease following allogeneic bone marrow transplantation in mice].
Li GP; Yang J; Hao J; Yang YM; Ren YN; Xie RF; Fan HH; Qian KC
Zhonghua Xue Ye Xue Za Zhi; 2012 Jun; 33(6):461-6. PubMed ID: 22967381
[TBL] [Abstract][Full Text] [Related]
17. Preemptive control of graft-versus-host disease in a murine allogeneic transplant model using retrovirally transduced murine suicidal lymphocytes.
Kornblau SM; Stiouf I; Snell V; Przepiorka D; Stephens LC; Champlin R; Marini FC
Cancer Res; 2001 Apr; 61(8):3355-60. PubMed ID: 11309292
[TBL] [Abstract][Full Text] [Related]
18. Suppression of lentivirus-mediated transgenic dendritic cells in graft-versus-host disease after allogeneic bone marrow transplantation in mice.
Xu YJ; Chen WR; Li DP; Song LX; Wu JQ; Zhang P; Li ZY; Huang YH
Genet Mol Res; 2015 Sep; 14(3):11444-55. PubMed ID: 26436385
[TBL] [Abstract][Full Text] [Related]
19. Host-derived CD8⁺ dendritic cells protect against acute graft-versus-host disease after experimental allogeneic bone marrow transplantation.
Weber M; Rudolph B; Stein P; Yogev N; Bosmann M; Schild H; Radsak MP
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1696-704. PubMed ID: 25132527
[TBL] [Abstract][Full Text] [Related]
20. IL-2-targeted therapy ameliorates the severity of graft-versus-host disease: ex vivo selective depletion of host-reactive T cells and in vivo therapy.
Yarkoni S; Prigozhina TB; Slavin S; Askenasy N
Biol Blood Marrow Transplant; 2012 Apr; 18(4):523-35. PubMed ID: 22227590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
